Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 170

1.

Presentation clinical, haematological and immunophenotypic features of 1081 patients with GPI-deficient (paroxysmal nocturnal haemoglobinuria) cells detected by flow cytometry.

Richards SJ, Dickinson AJ, Cullen MJ, Griffin M, Munir T, McKinley C, Mitchell LD, Newton DJ, Arnold L, Hill A, Hillmen P.

Br J Haematol. 2020 Feb 27. doi: 10.1111/bjh.16427. [Epub ahead of print]

PMID:
32103498
2.

See No Evil, Hear No Evil, Stop No Evil: Institutional-Level Tracking to Combat Mistreatment of Residents and Fellows.

Mustapha T, Ho Y, Andrews JS, Cullen MJ.

J Grad Med Educ. 2019 Oct;11(5):601-605. doi: 10.4300/JGME-D-19-00218.1.

PMID:
31636833
3.

The Stability Principle and global weak solutions of the free surface semi-geostrophic equations in geostrophic coordinates.

Cullen MJP, Kuna T, Pelloni B, Wilkinson M.

Proc Math Phys Eng Sci. 2019 Sep;475(2229):20180787. doi: 10.1098/rspa.2018.0787. Epub 2019 Sep 4.

PMID:
31611709
4.

Evaluation of the effects of chemotherapy-induced fatigue and pharmacological interventions in multiple mouse behavioral assays.

Dougherty JP, Springer DA, Cullen MJ, Gershengorn MC.

Behav Brain Res. 2019 Mar 15;360:255-261. doi: 10.1016/j.bbr.2018.12.011. Epub 2018 Dec 7.

5.

Predicting Performance of First-Year Residents: Correlations Between Structured Interview, Licensure Exam, and Competency Scores in a Multi-Institutional Study.

Marcus-Blank B, Dahlke JA, Braman JP, Borman-Shoap E, Tiryaki E, Chipman J, Andrews JS, Sackett PR, Cullen MJ.

Acad Med. 2019 Mar;94(3):378-387. doi: 10.1097/ACM.0000000000002429.

PMID:
30157088
6.

Taltirelin alleviates fatigue-like behavior in mouse models of cancer-related fatigue.

Dougherty JP, Wolff BS, Cullen MJ, Saligan LN, Gershengorn MC.

Pharmacol Res. 2017 Oct;124:1-8. doi: 10.1016/j.phrs.2017.07.012. Epub 2017 Jul 15.

7.

Utilization of an Active Site Mutant Receptor for the Identification of Potent and Selective Atypical 5-HT2C Receptor Agonists.

Carpenter J, Wang Y, Wu G, Feng J, Ye XY, Morales CL, Broekema M, Rossi KA, Miller KJ, Murphy BJ, Wu G, Malmstrom SE, Azzara AV, Sher PM, Fevig JM, Alt A, Bertekap RL Jr, Cullen MJ, Harper TM, Foster K, Luk E, Xiang Q, Grubb MF, Robl JA, Wacker DA.

J Med Chem. 2017 Jul 27;60(14):6166-6190. doi: 10.1021/acs.jmedchem.7b00385. Epub 2017 Jul 7.

PMID:
28635286
8.

Not all unprofessional behaviors are equal: The creation of a checklist of bad behaviors.

Cullen MJ, Konia MR, Borman-Shoap EC, Braman JP, Tiryaki E, Marcus-Blank B, Andrews JS.

Med Teach. 2017 Jan;39(1):85-91. doi: 10.1080/0142159X.2016.1231917. Epub 2016 Sep 27.

PMID:
27670731
9.

An Enantiomer of an Oral Small-Molecule TSH Receptor Agonist Exhibits Improved Pharmacologic Properties.

Neumann S, Padia U, Cullen MJ, Eliseeva E, Nir EA, Place RF, Morgan SJ, Gershengorn MC.

Front Endocrinol (Lausanne). 2016 Jul 27;7:105. doi: 10.3389/fendo.2016.00105. eCollection 2016.

10.

Non-basic azolotriazinone MCHR1 antagonists for the treatment of obesity: An empirical brain-exposures-driven candidate selection for in vivo efficacy studies.

Devasthale P, Wang W, Mignone J, Renduchintala K, Radhakrishnan S, Dhanapal J, Selvaraj J, Kuppusamy R, Pelleymounter MA, Longhi D, Huang N, Flynn N, Azzara AV, Rohrbach K, Devenny J, Rooney S, Thomas M, Glick S, Godonis H, Harvey S, Cullen MJ, Zhang H, Caporuscio C, Stetsko P, Grubb M, Huang C, Zhang L, Freeden C, Murphy BJ, Robl JA, Washburn WN.

Bioorg Med Chem Lett. 2015 Oct 15;25(20):4412-8. doi: 10.1016/j.bmcl.2015.09.018. Epub 2015 Sep 8.

PMID:
26386604
11.

Dihydropyrrolopyrazol-6-one MCHR1 antagonists for the treatment of obesity: Insights on in vivo efficacy from a novel FLIPR assay setup.

Devasthale P, Wang W, Hernandez AS, Moore F, Renduchintala K, Sridhar R, Pelleymounter MA, Longhi D, Huang N, Flynn N, Azzara AV, Rohrbach K, Devenny J, Rooney S, Thomas M, Glick S, Godonis H, Harvey S, Cullen MJ, Zhang H, Caporuscio C, Stetsko P, Grubb M, Huang C, Zhang L, Freeden C, Li YX, Murphy BJ, Robl JA, Washburn WN.

Bioorg Med Chem Lett. 2015 Jul 15;25(14):2793-9. doi: 10.1016/j.bmcl.2015.05.008. Epub 2015 May 15.

PMID:
26022839
12.

Identification of a nonbasic melanin hormone receptor 1 antagonist as an antiobesity clinical candidate.

Washburn WN, Manfredi M, Devasthale P, Zhao G, Ahmad S, Hernandez A, Robl JA, Wang W, Mignone J, Wang Z, Ngu K, Pelleymounter MA, Longhi D, Zhao R, Wang B, Huang N, Flynn N, Azzara AV, Barrish JC, Rohrbach K, Devenny JJ, Rooney S, Thomas M, Glick S, Godonis HE, Harvey SJ, Cullen MJ, Zhang H, Caporuscio C, Stetsko P, Grubb M, Maxwell BD, Yang H, Apedo A, Gemzik B, Janovitz EB, Huang C, Zhang L, Freeden C, Murphy BJ.

J Med Chem. 2014 Sep 25;57(18):7509-22. doi: 10.1021/jm500026w. Epub 2014 Sep 9.

PMID:
25165888
13.

Racial/ethnic subgroup differences in cognitive ability test range restriction: implications for differential validity.

Berry CM, Cullen MJ, Meyer JM.

J Appl Psychol. 2014 Jan;99(1):21-37. doi: 10.1037/a0034376. Epub 2013 Nov 4.

PMID:
24188390
14.

Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.

Ellsworth BA, Sher PM, Wu X, Wu G, Sulsky RB, Gu Z, Murugesan N, Zhu Y, Yu G, Sitkoff DF, Carlson KE, Kang L, Yang Y, Lee N, Baska RA, Keim WJ, Cullen MJ, Azzara AV, Zuvich E, Thomas MA, Rohrbach KW, Devenny JJ, Godonis HE, Harvey SJ, Murphy BJ, Everlof GG, Stetsko PI, Gudmundsson O, Johnghar S, Ranasinghe A, Behnia K, Pelleymounter MA, Ewing WR.

J Med Chem. 2013 Dec 12;56(23):9586-600. doi: 10.1021/jm4010835. Epub 2013 Nov 20.

PMID:
24182233
15.

Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.

Zhao G, Kwon C, Bisaha SN, Stein PD, Rossi KA, Cao X, Ung T, Wu G, Hung CP, Malmstrom SE, Zhang G, Qu Q, Gan J, Keim WJ, Cullen MJ, Rohrbach KW, Devenny J, Pelleymounter MA, Miller KJ, Robl JA.

Bioorg Med Chem Lett. 2013 Jul 1;23(13):3914-9. doi: 10.1016/j.bmcl.2013.04.061. Epub 2013 Apr 29.

PMID:
23683593
16.

Mathematics applied to the climate system: outstanding challenges and recent progress.

Williams PD, Cullen MJ, Davey MK, Huthnance JM.

Philos Trans A Math Phys Eng Sci. 2013 Apr 15;371(1991):20120518. doi: 10.1098/rsta.2012.0518. Print 2013 May 28.

17.

On the relationship between stratospheric structure and tropospheric blocking patterns.

Cullen MJ, Ngan K.

Philos Trans A Math Phys Eng Sci. 2013 Apr 15;371(1991):20120180. doi: 10.1098/rsta.2012.0180. Print 2013 May 28.

PMID:
23588047
18.

Diagnosis of boundary-layer circulations.

Beare RJ, Cullen MJ.

Philos Trans A Math Phys Eng Sci. 2013 Apr 15;371(1991):20110474. doi: 10.1098/rsta.2011.0474. Print 2013 May 28.

PMID:
23588045
19.

Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.

Fevig JM, Feng J, Rossi KA, Miller KJ, Wu G, Hung CP, Ung T, Malmstrom SE, Zhang G, Keim WJ, Cullen MJ, Rohrbach KW, Qu Q, Gan J, Pelleymounter MA, Robl JA.

Bioorg Med Chem Lett. 2013 Jan 1;23(1):330-5. doi: 10.1016/j.bmcl.2012.10.091. Epub 2012 Nov 2.

PMID:
23177783
20.

Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats.

Devenny JJ, Godonis HE, Harvey SJ, Rooney S, Cullen MJ, Pelleymounter MA.

Obesity (Silver Spring). 2012 Aug;20(8):1645-52. doi: 10.1038/oby.2012.59. Epub 2012 Mar 8.

21.

Comparative assessment of life cycle assessment methods used for personal computers.

Yao MA, Higgs TG, Cullen MJ, Stewart S, Brady TA.

Environ Sci Technol. 2010 Oct 1;44(19):7335-46. doi: 10.1021/es903297k. Review.

PMID:
20806933
22.

Aberrant expression of CD19 in AML with t(8;21) involves a poised chromatin structure and PAX5.

Walter K, Cockerill PN, Barlow R, Clarke D, Hoogenkamp M, Follows GA, Richards SJ, Cullen MJ, Bonifer C, Tagoh H.

Oncogene. 2010 May 20;29(20):2927-37. doi: 10.1038/onc.2010.56. Epub 2010 Mar 8.

PMID:
20208555
23.

Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization.

Hill A, Rother RP, Arnold L, Kelly R, Cullen MJ, Richards SJ, Hillmen P.

Haematologica. 2010 Apr;95(4):567-73. doi: 10.3324/haematol.2009.007229. Epub 2010 Feb 9.

24.

Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents.

Ahmad S, Ngu K, Miller KJ, Wu G, Hung CP, Malmstrom S, Zhang G, O'Tanyi E, Keim WJ, Cullen MJ, Rohrbach KW, Thomas M, Ung T, Qu Q, Gan J, Narayanan R, Pelleymounter MA, Robl JA.

Bioorg Med Chem Lett. 2010 Feb 1;20(3):1128-33. doi: 10.1016/j.bmcl.2009.12.014. Epub 2009 Dec 6.

PMID:
20022752
25.

Large eddy simulation of the atmosphere on various scales.

Cullen MJ, Brown AR.

Philos Trans A Math Phys Eng Sci. 2009 Jul 28;367(1899):2947-56. doi: 10.1098/rsta.2008.0268.

PMID:
19531514
26.

Development and evaluation of a stabilized whole-blood preparation as a process control material for screening of paroxysmal nocturnal hemoglobinuria by flow cytometry.

Richards SJ, Whitby L, Cullen MJ, Dickinson AJ, Granger V, Reilly JT, Hillmen P, Barnett D.

Cytometry B Clin Cytom. 2009 Jan;76(1):47-55. doi: 10.1002/cyto.b.20438. Epub 2008 Sep 5.

27.

Hypoglycaemia in an adult male: a surprising finding in pursuit of insulinoma.

Geraghty M, Draman M, Moran D, Muldoon C, Reynolds JV, Cullen MJ.

Surgeon. 2008 Feb;6(1):57-60.

PMID:
18318091
28.

Discovery of pyrazine carboxamide CB1 antagonists: the introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy of the series.

Ellsworth BA, Wang Y, Zhu Y, Pendri A, Gerritz SW, Sun C, Carlson KE, Kang L, Baska RA, Yang Y, Huang Q, Burford NT, Cullen MJ, Johnghar S, Behnia K, Pelleymounter MA, Washburn WN, Ewing WR.

Bioorg Med Chem Lett. 2007 Jul 15;17(14):3978-82. Epub 2007 Apr 29.

PMID:
17513109
29.

Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.

Wacker DA, Varnes JG, Malmstrom SE, Cao X, Hung CP, Ung T, Wu G, Zhang G, Zuvich E, Thomas MA, Keim WJ, Cullen MJ, Rohrbach KW, Qu Q, Narayanan R, Rossi K, Janovitz E, Lehman-McKeeman L, Malley MF, Devenny J, Pelleymounter MA, Miller KJ, Robl JA.

J Med Chem. 2007 Mar 22;50(6):1365-79. Epub 2007 Feb 23.

PMID:
17315987
30.

The role of mutant UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis.

Garringer HJ, Fisher C, Larsson TE, Davis SI, Koller DL, Cullen MJ, Draman MS, Conlon N, Jain A, Fedarko NS, Dasgupta B, White KE.

J Clin Endocrinol Metab. 2006 Oct;91(10):4037-42. Epub 2006 Jul 25.

PMID:
16868048
31.

High-resolution en-face visualization of the cardiomyocyte plasma membrane reveals distinctive distributions of spectrin and dystrophin.

Stevenson SA, Cullen MJ, Rothery S, Coppen SR, Severs NJ.

Eur J Cell Biol. 2005 Dec;84(12):961-71. Epub 2005 Oct 19.

PMID:
16325505
32.

Protection of erythrocytes from human complement-mediated lysis by membrane-targeted recombinant soluble CD59: a new approach to PNH therapy.

Hill A, Ridley SH, Esser D, Oldroyd RG, Cullen MJ, Kareclas P, Gallagher S, Smith GP, Richards SJ, White J, Smith RA, Hillmen P.

Blood. 2006 Mar 1;107(5):2131-7. Epub 2005 Dec 1.

PMID:
16322479
33.

Telephone-based psychiatry advice service for general practitioners.

Bradstock SE, Wilson AJ, Cullen MJ, Barwell KL.

Med J Aust. 2005 Jul 18;183(2):90. No abstract available.

PMID:
16022617
34.

Fibroblast growth factor-23 mutants causing familial tumoral calcinosis are differentially processed.

Larsson T, Davis SI, Garringer HJ, Mooney SD, Draman MS, Cullen MJ, White KE.

Endocrinology. 2005 Sep;146(9):3883-91. Epub 2005 Jun 16.

PMID:
15961556
35.

Two cases of hypothalamic-pituitary sarcoidosis.

Smith D, Cullen MJ.

J R Soc Med. 2005 Apr;98(4):167-9. No abstract available.

36.

A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis.

Larsson T, Yu X, Davis SI, Draman MS, Mooney SD, Cullen MJ, White KE.

J Clin Endocrinol Metab. 2005 Apr;90(4):2424-7. Epub 2005 Feb 1.

PMID:
15687325
37.

Neurocysticercosis: a rare cause of seizure.

Smith D, Ng V, Bonar M, Merry C, Bergin C, Cullen MJ, Nolan JJ.

Ir Med J. 2004 Oct;97(9):284-5.

PMID:
15568589
38.

The cost of managing diabetic foot ulceration in an Irish hospital.

Smith D, Cullen MJ, Nolan JJ.

Ir J Med Sci. 2004 Apr-Jun;173(2):89-92.

PMID:
15540710
39.

In vivo pharmacological characterization of indiplon, a novel pyrazolopyrimidine sedative-hypnotic.

Foster AC, Pelleymounter MA, Cullen MJ, Lewis D, Joppa M, Chen TK, Bozigian HP, Gross RS, Gogas KR.

J Pharmacol Exp Ther. 2004 Nov;311(2):547-59. Epub 2004 Jul 15.

PMID:
15256538
40.

Using SAT-grade and ability-job performance relationships to test predictions derived from stereotype threat theory.

Cullen MJ, Hardison CM, Sackett PR.

J Appl Psychol. 2004 Apr;89(2):220-30.

PMID:
15065971
41.

Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.

Hillmen P, Hall C, Marsh JC, Elebute M, Bombara MP, Petro BE, Cullen MJ, Richards SJ, Rollins SA, Mojcik CF, Rother RP.

N Engl J Med. 2004 Feb 5;350(6):552-9.

42.

On interpreting stereotype threat as accounting for African American-White differences on cognitive tests.

Sackett PR, Hardison CM, Cullen MJ.

Am Psychol. 2004 Jan;59(1):7-13.

PMID:
14736315
43.

Rapid diagnosis of acute promyelocytic leukemia (PML): applicability of flow cytometry and PML protein immunofluorescence.

Cullen MJ, Richards SJ, O'Connor SJ, Dickinson H, Sharpe C, Swirsky DM, Owen R.

Cancer Genet Cytogenet. 2004 Jan 15;148(2):176-7. No abstract available.

PMID:
14734236
44.

Development and progression of a Philadelphia-chromosome-negative acute myelocytic leukemia clone in a patient with Philadelphia-chromosome-positive chronic myelocytic leukemia.

Cullen MJ, Richards SJ, Dickinson H, Carter C, Swirsky DM, Owen RG.

Cancer Genet Cytogenet. 2004 Jan 15;148(2):170-3.

PMID:
14734234
45.

Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia.

Rawstron AC, Kennedy B, Moreton P, Dickinson AJ, Cullen MJ, Richards SJ, Jack AS, Hillmen P.

Blood. 2004 Mar 15;103(6):2027-31. Epub 2003 Nov 20.

PMID:
14630811
46.

Muscle fibre breakdown in venom-induced muscle degeneration.

Harris JB, Vater R, Wilson M, Cullen MJ.

J Anat. 2003 Apr;202(4):363-72.

47.

The Healthline pilot: call centre triage in New Zealand.

St George IM, Cullen MJ.

N Z Med J. 2001 Sep 28;114(1140):429-30.

PMID:
11700752
48.

Calcium currents and transients in co-cultured contracting normal and Duchenne muscular dystrophy human myotubes.

Imbert N, Vandebrouck C, Duport G, Raymond G, Hassoni AA, Constantin B, Cullen MJ, Cognard C.

J Physiol. 2001 Jul 15;534(Pt. 2):343-55.

49.

Urocortin, corticotropin releasing factor-2 receptors and energy balance.

Cullen MJ, Ling N, Foster AC, Pelleymounter MA.

Endocrinology. 2001 Mar;142(3):992-9.

PMID:
11181511
50.

Growth factor supplemented matrigel improves ectopic skeletal muscle formation--a cell therapy approach.

Barbero A, Benelli R, Minghelli S, Tosetti F, Dorcaratto A, Ponzetto C, Wernig A, Cullen MJ, Albini A, Noonan DM.

J Cell Physiol. 2001 Feb;186(2):183-92.

PMID:
11169455

Supplemental Content

Loading ...
Support Center